Lowinger
Benjamin Lowinger, New York, NY US
Patent application number | Description | Published |
---|---|---|
20130256498 | Universal Object Retention System With Tactile Feature - Various embodiments may be generally directed to a universal object retention system that may be configured with at least a support substrate and a plurality of ductile members extending across predetermined portions of the support substrate. At least one ductile member may be configured with a tactile feature that increases friction between the support substrate and the ductile feature. | 10-03-2013 |
20140131546 | Universal Object Retention System With Tactile Feature - Various embodiments may be generally directed to a universal object retention system that may be configured with at least a support substrate and a plurality of ductile members extending across predetermined portions of the support substrate. At least one ductile member may be configured with a tactile feature that increases friction between the support substrate and the ductile feature. | 05-15-2014 |
Bruno Lowinger, Ann Arbor, MI US
Patent application number | Description | Published |
---|---|---|
20130030324 | MALIGNANCY REMOVAL WITH TISSUE ADHESIVE SECURED STRUCTURE - Processes of preventing tumor cell mestastases induced by surgical procedures such as resection or biopsy are provided. Some embodiments include applying a tissue adhesive to a structure that is then adhered to tissue providing a tensioning surface for exposing normal tissue for cutting thereby preventing contact of a surgical instrument with tumor tissue. Methods of preventing tumor cell metastasis during or following biopsy are also provided whereby an adhesive alone or optionally along with a structure occupy a track left by a biopsy needle and provide a physical barrier between tumor tissue and normal tissue. The inventive processes improve patient outcome by reducing surgically induced tumor cell metastases. | 01-31-2013 |
20130190788 | METHODS AND COMPOSITIONS FOR REPAIR OF VASCULAR TISSUE - Processes for the correction or treatment of a vascular defect or vascularized tumor are provided including introducing an embolus formed of an adhesive to occlude an area of a defect or to prevent blood flow to a tumor. The inventive processes provide simple methods for long-term correction of vascular defects. | 07-25-2013 |
Bruno Lowinger, Saline, MI US
Patent application number | Description | Published |
---|---|---|
20090287313 | TISSUE ADHESIVE SEALANT - A tissue adhesive sealant includes a cross-linkable protein in a solution that when combined with a cross-linking agent solution including an aldehyde and amino acid containing species reactive with the aldehyde cross-links to form a seal. The sealant is well suited for bonding tissue alone or in combination with a patch. The ratio between the aldehyde and the amino acid containing species is between 20:1 and 1:1 on an aldehyde moiety:amino acid or peptide subunit molar basis. Particularly strong seals are formed when the protein and cross-linking agent are present in a molar ratio of between 15:1 and 1:1. | 11-19-2009 |
Jack Lowinger, Lawrence, NY US
Patent application number | Description | Published |
---|---|---|
20140351080 | SYSTEM AND METHOD FOR JOINT SHOPPING CART - A method and system may include receiving input, by a processor, from a first user. The input may describe one or more items sold by a retailer, and the first user may be part of a group of users. The method may include adding the one or more items to a shopping cart associated with the group of users. The method may further include assigning at least one administrative function to each user of the group of users and displaying administrative functions of the shopping cart to each user of the group of users, based on each user's assigned administrative function. | 11-27-2014 |
20140351082 | SYSTEM AND METHOD FOR JOINT SHOPPING CART - A method and system may include receiving input, by a processor, from a first user. The input may describe one or more items sold by a retailer, and the first user may be part of a group of users. The method may include adding the one or more items to a shopping cart associated with the group of users. The method may further include assigning at least one administrative function to each user of the group of users and displaying administrative functions of the shopping cart to each user of the group of users, based on each user's assigned administrative function. | 11-27-2014 |
Johan Lowinger, Dexter, MI US
Patent application number | Description | Published |
---|---|---|
20090287313 | TISSUE ADHESIVE SEALANT - A tissue adhesive sealant includes a cross-linkable protein in a solution that when combined with a cross-linking agent solution including an aldehyde and amino acid containing species reactive with the aldehyde cross-links to form a seal. The sealant is well suited for bonding tissue alone or in combination with a patch. The ratio between the aldehyde and the amino acid containing species is between 20:1 and 1:1 on an aldehyde moiety:amino acid or peptide subunit molar basis. Particularly strong seals are formed when the protein and cross-linking agent are present in a molar ratio of between 15:1 and 1:1. | 11-19-2009 |
Johan Lowinger, Bloomington, IN US
Patent application number | Description | Published |
---|---|---|
20140187943 | ANGLED NEEDLE ENTRY - An angle assist block for transcutaneous insertion of a needle for a patient is provided. The angle assist block comprises a body portion having an outer surface wherein the outer surface comprises a first side and a second side. The first side is configured to engage skin tissue and the second side opposes the first side. The angle assist block further comprises at least one channel formed through the body portion from the first side to the second side. The channel is angled relative to the first side defining an angle and to allow the needle to be inserted through the channel and transcutaneously introduced at the angle. The angle assist block comprises an attachment portion attached to the outer surface. The attachment portion is configured to removably attach to an attachment receiving member of a tissue visualization device. | 07-03-2014 |
Johan M. Lowinger, Bloomington, IN US
Patent application number | Description | Published |
---|---|---|
20100004606 | Deployment assembly and introducer - A deployment assembly ( | 01-07-2010 |
20110184507 | MULTI-SECTION STENT - A multi-section tubular device suitable for use as a stent is provided. The multisection tubular device includes a first tubular section ( | 07-28-2011 |
Michael Lowinger, Norristown, PA US
Patent application number | Description | Published |
---|---|---|
20100227903 | Polymer Formulations of CETP Inhibitors - A pharmaceutical composition comprises (a) a CETP inhibiting compound, or a pharmaceutically acceptable salt thereof; (b) a concentration-enhancing polymer, and (c) optionally one or more surfactants; wherein the compound has the structure shown as Formula I below. The composition raises HDL-cholesterol and lowers LDL-cholesterol. | 09-09-2010 |
Timothy Lowinger, Guilford, CT US
Patent application number | Description | Published |
---|---|---|
20090054424 | Optically active pyridine derivative and a medicament containing the same - An optically active (−)-7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-5-[(3S)-3-piperidinyl]-1,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one of the formula: | 02-26-2009 |
Timothy Lowinger, Nishinomiya City JP
Patent application number | Description | Published |
---|---|---|
20140329866 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS - This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy. | 11-06-2014 |
Timothy B. Lowinger, Nishinomiya JP
Patent application number | Description | Published |
---|---|---|
20080300281 | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas - This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy. | 12-04-2008 |
20090093526 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS - This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy. | 04-09-2009 |
20120046290 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS - This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy. | 02-23-2012 |
20120149706 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS - This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy. | 06-14-2012 |
20120270878 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS - This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy. | 10-25-2012 |
Timothy B. Lowinger, Guilford, CT US
Patent application number | Description | Published |
---|---|---|
20100204213 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS - The present invention relates to a sulfonamide derivative which is useful as an active ingredient of pharmaceutical preparations. The sulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders. | 08-12-2010 |
Timothy B. Lowinger, Nishinomiya City JP
Patent application number | Description | Published |
---|---|---|
20080269265 | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas - This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy. | 10-30-2008 |
20090118268 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS - This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy. | 05-07-2009 |
20120040986 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS - This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy. | 02-16-2012 |
20120129893 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas - Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se. | 05-24-2012 |
20120142742 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS - This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy. | 06-07-2012 |
Timothy B. Lowinger, Carlisle, MA US
Patent application number | Description | Published |
---|---|---|
20100305149 | Polyal Drug Conjugates Comprising Variable Rate-Releasing Linkers - Polyal-Drug conjugates comprising a variable rate-releasing linker are described along with methods of making such conjugates. Uses for such Polyal-Drug conjugates is also described. | 12-02-2010 |
20110243880 | MODIFIED POLYMERS FOR DELIVERY OF POLYNUCLEOTIDES, METHOD OF MANUFACTURE, AND METHODS OF USE THEREOF - A polynucleotide delivery vehicle comprising a modified polymer is provided herein, the modified polymer having the following formula: | 10-06-2011 |
20120321583 | Protein-Polymer-Drug Conjugates - A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L | 12-20-2012 |
20130101546 | Protein-Polymer-Drug Conjugates - A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L | 04-25-2013 |
20130109817 | Modified Polymers for Delivery of Polynucleotides, Method of Manufacture, and Methods of Use Thereof | 05-02-2013 |
20130189218 | PHARMACEUTICAL FORMULATIONS FOR FUMAGILLIN DERIVATIVE-PHF CONJUGATES - The invention described herein provides a mixture comprising polymer molecules or salts thereof, wherein a polymer molecule in the mixture comprises covalently bound subunits L, K, and M wherein the average molecular weight of the polymer molecules in the mixture is about 50 kDa to about 200 kDa, wherein the mole percentage of subunit M, K and L, relative to the total amount of subunits in the mixture, is about 90.5 to about 96 mol %, about 2.8 to about 7.3 mol %, and about 1.2 to about 2.2 mol %, respectively. | 07-25-2013 |
20130309192 | Auristatin Compounds and Conjugates Thereof - Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L | 11-21-2013 |
20140017265 | Terminally Modified Polymers and Conjugates Thereof - A terminally modified polymer is provided herein. At least one terminus of the polymer is —O—(CH | 01-16-2014 |
20140134127 | Protein-Polymer-Drug Conjugates - A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L | 05-15-2014 |
20150044160 | PROTEIN-POLYMER-DRUG CONJUGATES - A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L | 02-12-2015 |
20150064130 | PROTEIN-POLYMER-DRUG CONJUGATES - Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L | 03-05-2015 |